Please use this identifier to cite or link to this item: https://dspace.ctu.edu.vn/jspui/handle/123456789/54539
Full metadata record
DC FieldValueLanguage
dc.contributor.authorĐỗ, Thị Diệu Hằng-
dc.contributor.authorĐinh, Thị Minh Hảo-
dc.contributor.authorNguyễn, Hoàng Thanh Vân-
dc.contributor.authorHoàng, Thị Kim Huyền-
dc.date.accessioned2021-06-08T08:05:43Z-
dc.date.available2021-06-08T08:05:43Z-
dc.date.issued2018-
dc.identifier.issn0866-7861-
dc.identifier.urihttps://dspace.ctu.edu.vn/jspui/handle/123456789/54539-
dc.description.abstractThe drug use ofDMARD (Disease Modifying Anti Rheumatic Drug) at the Nephrology- Musculoskeletal Department of Hue Central Hospital was evaluated on 26 patients with rheumatoid arthritis (RA). The rates of indication and dosage in accordance with the guidelines were above 68% and 95%, respectively. After 6 months’ treatment, the C-reactive protein and hemoglobin levels were improved from the baseline. Transaminase increased to grade 1 in 9.1% - 38.1% of the patients. In neutrophil count, decrease was observed in 5.3% - 31.7% of the patients. The major abnormalities were grade 1 neutropenia and grade 2 neutropenia. As a result, for appropriate management of drug use in general, better Monitoring Adverse Drug Reaction in RA patients was required.vi_VN
dc.language.isovivi_VN
dc.relation.ispartofseriesTạp chí Dược học;Số 506 .- Tr.5-9-
dc.subjectRAvi_VN
dc.subjectDMARDvi_VN
dc.subjectC + eactive proteinvi_VN
dc.subjectHemoglobinvi_VN
dc.subjectNeutropeniavi_VN
dc.titleĐánh giá sử dụng thuốc trong điều trị viêm khớp dạng thấp tại Khoa Nội thận - Cơ xương khớp Bệnh viện Trung ương Huếvi_VN
dc.typeArticlevi_VN
Appears in Collections:Dược học

Files in This Item:
File Description SizeFormat 
_file_
  Restricted Access
3.54 MBAdobe PDF
Your IP: 18.226.187.232


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.